ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research

On June 18, 2020 ArcherDX, Inc. reported it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy (Press release, ArcherDX, JUN 18, 2020, View Source [SID1234561239]). PCM provides tumor-informed longitudinal analysis of circulating tumor DNA (ctDNA) found in patient blood where the quantity of ctDNA is a predictor of disease stage and burden, and achieves accuracy at low limits of detection by focusing the ctDNA analysis on known patient-specific mutations found in the tumor tissue.i ArcherDX and BMS will evaluate the clinical samples from cancer patient cohorts with the goal of advancing the use of MRD detection or ctDNA clearance to potentially inform future therapy selection and/or optimization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Collaborating with BMS, a leader in oncology, is a significant step toward accomplishing our common goal of improving patient outcomes. We are delighted BMS chose to leverage our Personalized Cancer Monitoring assays for clinical research aimed at expanding precision oncology into early-stage cancers, when the cancer is typically easier to cure compared to late-stage cancers," said Jason Myers, Chief Executive Officer and co-founder of ArcherDX. "This collaboration further underscores our intention to facilitate real-time monitoring of ctDNA during and after therapy with personalized, decentralized assays that can be distributed across the globe and could potentially optimize the use of current and future cancer therapies."

ArcherDX’s PCM development program is being advanced by ArcherDX and is supported by a collaboration led by Professor Charles Swanton of UCL and the Francis Crick Institute to detect evidence of disease progression in lung cancer patients from cell-free ctDNA as part of the Cancer Research UK-funded UCL-sponsored TRACERx study.[1] PCM applies ArcherDX’s proprietary Anchored Multiplex PCR (AMP) technology to accurately detect exceedingly low levels of cancer-derived DNA from patient blood.

About Personalized Cancer Monitoring
PCM is a patient-specific assay for monitoring residual disease, disease recurrence and progression of cancer. At initial diagnosis, exome sequencing of the surgically removed tumor or a tumor biopsy is used to identify patient-specific cancer mutations. A patient-specific assay is delivered to the laboratory affiliated with the patient’s care team. Clinicians use the personalized assay to measure ctDNA taken from non-invasive peripheral blood draws at specified intervals, producing a quantitative longitudinal view of the cancer’s evolution.

PCM is currently available and sold under a research use only (RUO) designation and is not yet approved for broad clinical use. Once it receives regulatory approval, PCM could ultimately expand the use of precision oncology to early-stage cancers, potentially providing faster diagnostic solutions in the future at local and regional laboratories inside and outside the U.S.

Tecentriq in combination with chemotherapy meets primary endpoint, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

On June 18, 2020 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that the Phase III IMpassion031 study met its primary endpoint, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer (Press release, Chugai, JUN 18, 2020, View Source [SID1234561207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMpassion031 study is evaluating Tecentriq in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy. The study met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression. The IMpassion031 study is the second positive phase III study demonstrating the benefit of Tecentriq in TNBC, and the first Tecentriq study to demonstrate benefit in early TNBC.

Safety for the Tecentriq combination appeared consistent with the known safety profiles of the individual medicines and no new safety signals were identified. Results of the IMpassion031 study will be presented at an upcoming medical meeting and will be discussed with global health authorities including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

"Tecentriq is the first approved immune checkpoint inhibitor in the breast cancer field. We are pleased that Tecentriq showed positive results in the treatment of the early TNBC," said Dr. Osamu Okuda, Chugai’s President and COO. "TNBC is an aggressive and rapidly progressing disease with limited treatment options, and there are high unmet medical needs. We will be working together with Roche to provide patients with this new treatment option as early as possible."

About the IMpassion031 study
The IMpassion031 study is a Phase III, multicenter, randomized, double-blind study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy, in people with previously untreated, early TNBC. The study enrolled 333 people who were randomized in a 1:1 ratio to receive Tecentriq or placebo plus chemotherapy in the neoadjuvant (before surgery) setting. The primary endpoint is pCR using the American Joint Committee on Cancer (AJCC) staging system in the ITT population and in the PD-L1-positive population.

About Triple-Negative Breast Cancer (TNBC)
In Japan, 92,200 women (2019 predicted value) are estimated to be afflicted with breast cancer each year. 15,100 women in Japan (2019 predicted value) die as a result of the disease.1) Triple-negative breast cancer accounts for 15% of all breast cancer cases and, is more common in women under the age of 50, compared with other forms of breast cancer.2-4) Triple-negative breast cancer is defined by the lack of expression of hormone receptors (estrogen and progesterone receptors) and the overexpression of human epidermal growth factor receptor 2 (HER2). In general, triple-negative breast cancer has a high tumor-proliferative capacity and shorter overall survival, compared with other forms of breast cancer.3, 5)

Trademarks used or mentioned in this release are protected by law.

Sources

Project Cancer Statistics, 2019. Cancer Information Service, National Cancer Center, Japan. [Internet; cited June, 2020] Available from: View Source
Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–1924.
BreastCancer.org. What is Triple-Negative Breast Cancer? [Internet; June, 2020] Available from: View Source
Cancer Treatment Centers of America. Triple negative breast cancer risk factors. [Internet; cited June, 2020]
View Source
Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627-636.

Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates

On June 18, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SEA-TGT, also known as SGN-TGT, an anti-TIGIT antibody for patients with solid tumors and lymphomas. TIGIT (T-cell immune receptor with Ig and ITIM domains) is an inhibitory immune receptor that is emerging as a clinically relevant immuno-oncology target (Press release, Seattle Genetics, JUN 18, 2020, View Source [SID1234561223]). SEA-TGT is a nonfucosylated human IgG1 antibody that uses the Company’s proprietary Sugar Engineered Antibody (SEA) technology. The Company also announced the dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SGN-B6A, an antibody-drug conjugate (ADC) targeting integrin beta-6, which is overexpressed in numerous solid tumors and has been demonstrated to be a negative prognostic indicator across a diverse range of cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical data indicate that SEA-TGT has enhanced effector function enabled by the Company’s SEA technology. These data indicate that SEA-TGT may have best-in-class potential through enhanced depletion of TIGIT-positive regulatory T-cells (Tregs), distinct immune changes including amplified naïve and memory T-cell responses, and induction of innate immune cell activation. Curative anti-tumor activity in preclinical models was observed as a single agent and in combination with a PD-1 checkpoint inhibitor. These data support potential for improved monotherapy and combinatorial clinical activity as compared to a non-enhanced TIGIT antibody.

SGN-B6A is an ADC targeting integrin beta-6 to deliver the clinically validated payload monomethyl auristatin E (MMAE). In preclinical research, this ADC has demonstrated in vivo activity in models spanning a range of antigen expression levels and tumor types.

"We believe that anti-TIGIT antibodies may have an important therapeutic role in the evolving immuno-oncology landscape," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. "SEA-TGT utilizes our novel SEA technology, which in preclinical research has demonstrated enhanced effector function that potentially differentiates it from other TIGIT antibodies in the clinic. The initiation of clinical trials for both SEA-TGT and the ADC, SGN-B6A, underscore our commitment to advancing novel drug candidates from our pipeline into clinical testing."

SEA-TGT Phase 1 Trial

The phase 1 trial of SEA-TGT will evaluate the safety and anti-tumor activity of SEA-TGT as a single agent as well as in combination with the anti-PD-1 antibody, pembrolizumab. The phase 1 trial will evaluate SEA-TGT in advanced solid tumors and lymphomas, including non-small cell lung cancer, gastric carcinoma, Hodgkin and selected non-Hodgkin lymphomas. The study is currently open in multiple sites in the United States and is expected to enroll approximately 111 participants. More information about the study of SEA-TGT is available at clinicaltrials.gov.

SGN-B6A Phase 1 Trial

SGN-B6A is an ADC targeting integrin beta-6 to deliver the clinically validated payload MMAE. The phase 1 trial will evaluate SGN-B6A in solid tumors, including non-small cell lung cancer, head and neck squamous cell cancer, breast, esophageal, ovarian, bladder, cervical and gastric cancers. The study is currently open in multiple sites in the United States and is expected to enroll approximately 235 participants. More information about the study of SGN-B6A is available at clinicaltrials.gov.

Incyte Investor Conference Update

On June 17, 2020 Incyte (Nasdaq:INCY) reported that it has updated its presentation time at the following investor conference (Press release, Incyte, JUN 17, 2020, View Source [SID1234561175]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).
The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

Agenus to Present at the Raymond James Virtual Human Health Innovation Conference

On June 17, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, reported that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus’ progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020 (Press release, Agenus, JUN 17, 2020, View Source [SID1234561191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, June 18, 2020

Time: 4:20 pm – 4:450 p.m. ET / Virtual Track 1

Webcast: The presentation will be webcast and can be accessed through the following link: View Source